Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Non Operating Income (2019 - 2022)

Goldenwell Biotech filings provide 4 years of Non Operating Income readings, the most recent being $1.0 for Q2 2022.

  • On a quarterly basis, Non Operating Income fell 99.62% to $1.0 in Q2 2022 year-over-year; TTM through Mar 2023 was $1.0, a 99.96% decrease, with the full-year FY2022 number at $8.0, down 99.38% from a year prior.
  • Non Operating Income hit $1.0 in Q2 2022 for Goldenwell Biotech, down from $7.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1272.0 in Q3 2021 to a low of -$12.0 in Q4 2019.
  • Median Non Operating Income over the past 4 years was $18.0 (2020), compared with a mean of $334.9.
  • Biggest five-year swings in Non Operating Income: skyrocketed 25340.0% in 2021 and later plummeted 99.62% in 2022.
  • Goldenwell Biotech's Non Operating Income stood at -$12.0 in 2019, then soared by 141.67% to $5.0 in 2020, then surged by 20460.0% to $1028.0 in 2021, then crashed by 99.9% to $1.0 in 2022.
  • The last three reported values for Non Operating Income were $1.0 (Q2 2022), $7.0 (Q1 2022), and $1028.0 (Q4 2021) per Business Quant data.